Selective estrogen receptor modulators: Structure, function, and clinical use

Journal of Clinical Oncology

Volumn 18, Issue 17, 2000, Pages 3172-3186

  Osborne, C Kent ^a  

^a Holly)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ARZOXIFENE; DROLOXIFENE; ESTROGEN RECEPTOR; FULVESTRANT; IDOXIFENE; MIPROXIFENE PHOSPHATE; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PREVENTION; CARCINOMA IN SITU; ESTROGEN BLOOD LEVEL; GENE TARGETING; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; METASTASIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

EID: 0033855713     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.17.3172     Document Type: Article

References (145)

1. Steroid hormone receptors in breast cancer management
2. Drug therapy: Tamoxifen in the treatment of breast cancer
3. Tamoxifen and secondary tumours: An update
4. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
5. Identification and characterization of a novel human estrogen receptor
6. The complete primary structure of human estrogen receptor beta (hER-beta) and its heterodimerization with ER alpha in vivo and in vitro
7. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonist
8. Interaction of estrogenic chemical and phytoestrogens with estrogen receptor beta
9. The carboxy-terminal F domain of the human estrogen receptor: Role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists
10. Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor
11. Functional domains of the human estrogen receptor
12. The human estrogen receptor has two independent nonacidic transcriptional activation functions
13. The transcription activation function located in the hormone-binding domain of the human oestrogen receptor is not encoded by a single exon
14. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
15. A comparison of transcriptional activation by ER alpha and ER beta
16. Analysis of estrogen receptor function in vitro reveals distinct classes of antiestrogens
17. A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor
18. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
19. Identification of an estrogen response element activated by metabolites of 17-beta-estradiol and raloxifene
20. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha
21. Estrogen receptors alpha and beta form heterodimers on DNA
22. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
23. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites
24. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
25. Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo
26. Interactions between the oestrogen and insulin-like growth factor signaling pathways in the control of breast epithelial cell proliferation
27. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
28. Molecular basis of agonism and antagonism in the oestrogen receptor
29. Nuclear receptor coactivators and corepressors
30. Nuclear receptor coregulators: Cellular and molecular biology
31. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
32. Proteasomal regulation of nuclear receptor corepressor-mediated repression
33. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily
34. Chromatin remodeling by the glucocorticoid receptor requires the BRG1 complex
35. The putative cofactor TIF1a is a protein kinase that is hyperphosphorylated upon intraction with liganded nuclear receptors
36. BRCA-1 inhibition of estrogen receptor signaling in transfected cells
37. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N/CoR or SMRT
38. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-Hydroxytamoxifen
39. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
40. Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use
41. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment
42. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer
43. Antiestrogens: Tamoxifen, SERMs and beyond
44. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer
45. A randomized clinical thai evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
46. Symptoms associated with tamoxifen treatment in postmenopausal women
47. Tamoxifen inhibits arterial accumulation in LDL degradation products and progression of coronary artery atherosclerosis in monkeys
48. Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial: The Scottish Breast Cancer Committee
49. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in randomized trial of adjuvant tamoxifen
50. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
51. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
52. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
53. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer
54. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
55. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
56. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism
57. A new triphenylethylene compound Fc-1157A: II. Antitumor effects
58. Antiestrogen action of toremifene on hormone-dependent, independent and heterogeneous breast tumor growth in the athymic mouse
59. Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl;cd (BR) rats
60. Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with 2 antiestrogens
61. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
62. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
63. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients
64. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer
65. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
66. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
67. Preclinical data for droloxifene
68. The estrogenic and antiestrogenic activities of droloxifene in human breast cancer
69. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats
70. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen and 4-hydroxytamoxifen
71. Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
72. Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes: Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites
73. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer
74. The novel antioestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired antiestrogen resistance
75. Idoxifene: A novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats
76. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
77. Idoxifene: Report of a phase I study in patients with metastatic breast cancer
78. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors
79. Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice
80. A new triphenylethylene derivative TAT-59: Hormone receptors, insulin-like growth factor 1 and growth suppression of hormone dependent MCF-7 tumors in athymic mice
81. 3-(4-(1,2-diphenylbut-1-enyl)phenyl)acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats
82. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone
83. Basic guide to the mechanisms of antiestrogen action
84. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors
85. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro
86. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice
87. Long-term inhibitory effects of a novel antiestrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice
88. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
89. Antagonism of estrogen action with a new benzothiophene-derived antiestrogen
90. Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen
91. Effects of antiestrogens on bone in castrated and intact female rats
92. The antitumor action of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
93. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice
94. Raloxifene
95. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen and ICI 164,384, a new steroidal antiestrogen in ZR-75-1 human breast cancer cells
96. Effects of a new antiestrogen keoxifene (LY 156758) on growth of carcinogen induced mammary tumors and on LH and prolactin levels
97. Raloxifene (LY139481-HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
98. Synthesis and pharmacology of conformationally restricted raloxifene analogues: Highly potent selective estrogen receptor modulators
99. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyl)b enzo[b]thiophene: A novel, highly potent, selective estrogen receptor modulator
100. LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo
101. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models
102. A potent specific pure antiestrogen with clinical potential
103. Use of pure antioestrogens to elucidate the mode of action of oestrogens
104. Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization
105. Antiestrogen ICI 164,384 reduces a cellular estrogen receptor content by increasing its turnover
106. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
107. Antagonism of estrogen- and antiestrogen-induced uterine complement component C3 expression by ICI 164,384
108. Contrasting effects of tamoxifen and ICI 182780 on estrogen-induced calbindin-D 9k gene expression in the uterus and in primary culture of myometrial cells
109. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780
110. Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780
111. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats
112. The future of new pure antioestrogens in clinical breast cancer
113. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAM(R)-1
114. ICI 182,780: A pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain
115. The effect of raloxifene on risk of breast cancer in postmenopausal women
116. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
117. Interim analysis of the incident breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial
118. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomized women
119. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
120. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
121. Toremifene: A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer
122. Phase II and III clinical trials of toremifene for metastatic breast cancer
123. Tamoxifen rechallenge: Response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer
124. Preliminary results of two multi-center trials comparing the efficacy and tolerability of arimidex (anastrozole) and tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC)
125. Tamoxifen resistance in breast cancer
126. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
127. Raloxifene HCl, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer
128. Phase II evaluation of Ly156758 in metastatic breast cancer
129. Pharmacodynamics and pharmacokinetics of LY353381.HCl, a selective estrogen receptor modulator (SERM), in women (pts) with refractory, metastatic breast cancer (MBC)
130. A phase II randomised double-blind study of idoxifene (40 mg/d) vs. tamoxifen (40 mg/d) in patients with locally advanced/metastatic breast cancer resistant to tamoxifen (20 mg/d)
131. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
132. Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen-resistant breast cancer
133. Tamoxifen for early breast cancer: An overview of the randomised trials
134. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
135. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: The Scottish Cancer Trails Breast Group
136. Cardiac and thromboembolic morbidity among post-menopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group
137. Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen trial: The Scottish Breast Cancer Committee
138. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
139. Gynecological effects of tamoxifen and the association with endometrial cancer
140. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy
141. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial